Avalo Therapeutics, Inc.
USD18.20
+0.20 (+1.11%)
CEO
Garry A. Neil
IPO Date
2015-10-14
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Country
US
Open
$18.29
Prev. Close
$18.00
Day Low
$17.65
Day High
$18.46
52W Low
$4.61
52W High
$24.27
Market Cap
$0.21B
Volume
8.58M
| 1,450 |
| $18.00 |
| 25 Jun 2026 | Doyle Mittie | Chief Medical Officer | M-Exempt | Disposed | 1,450 | $8.04 |
| 25 Jun 2026 | Philip Ron M | director | A-Award | Acquired | 40,200 | $17.83 |
| 25 Jun 2026 | Philip Ron M | — | Disposed | 0 | $0.00 |
| 12 Jun 2026 | Riley Jennifer | Chief Strategy Officer | F-InKind | Disposed | 588 | $13.10 |
| 12 Jun 2026 | VARKI PAUL | Chief Legal Officer | F-InKind | Disposed | 1,081 | $13.10 |
| 12 Jun 2026 | Sullivan Christopher Ryan | Chief Financial Officer | F-InKind | Disposed | 138 | $13.10 |
| 12 Jun 2026 | Doyle Mittie | Chief Medical Officer | F-InKind | Disposed | 1,084 | $13.10 |
| 4 Jun 2026 | Lind Kevin Robert | director | A-Award | Acquired | 20,100 | $13.96 |